Lumida
/PBYI
⌘K
Puma Biotechnology Inc

Puma Biotechnology Inc

PBYI
$9.12USD↓-0.55%-0.05 today

MARKET CAP

470.8M

P/E (TTM)

17.6x

FWD P/E

22.0x

DAY RANGE

$9 – $9

52W RANGE

$4
$10

AI Summary

Stalk
Sell NowMedium

The asset exhibits a classic blow-off top with a long upper wick and high-volume exhaustion in Stage 2, suggesting medium-term reversal risk; short-term rejection at resistance and overbought conditions favor immediate bearish engagement through a sell now posture, targeting the recent resistance zone with rejection-based execution.

  • ↑Q2 total revenue $56.5M (up from $49.2M YoY); NERLYNX product sales +27% QoQ.
  • ↑2026 revenue guidance raised to $205–209M, reflecting strong market demand.
  • ↓NERLYNX drives majority of sales, posing single‐product concentration risk.
Full analysis →

Buying

1

institutions

Selling

7

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

BUY3.80 M30.86 M+205.78 K+34.2%0.00%
RT

Renaissance Technologies LLC

Q2 2026

SELL1.84 M14.89 M+-106.20 K+20.0%0.02%
AC

Aqr Capital Management LLC

Q2 2026

SELL725.19 K5.88 M+-75.00 K+15.0%0.00%
MM

Millennium Management LLC

Q2 2026

SELL602.24 K4.88 M+-875.28 K-48.3%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

SELL211.34 K1.73 M+-9.38 K+27.9%0.00%
MG

Man Group Plc

Q2 2026

SELL41.51 K336.61 K+-5.87 K+11.2%0.00%
RC

Rockefeller Capital Management L.P.

Q2 2026

SELL375.003.04 K+-418.00-40.0%0.00%
CA

Citadel Advisors LLC

Q2 2026

SELL0.000.00+-29.96 K-100.0%0.00%